Adaptive Biotechnologies Files 8-K on Financials
Ticker: ADPT · Form: 8-K · Filed: Apr 5, 2024 · CIK: 1478320
| Field | Detail |
|---|---|
| Company | Adaptive Biotechnologies Corp (ADPT) |
| Form Type | 8-K |
| Filed Date | Apr 5, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-K
Related Tickers: ADPT
TL;DR
ADPT filed an 8-K on April 2nd detailing financial results.
AI Summary
Adaptive Biotechnologies Corporation filed an 8-K on April 5, 2024, reporting on its results of operations and financial condition as of April 2, 2024. The filing details financial statements and exhibits related to the company's performance.
Why It Matters
This 8-K filing provides crucial updates on Adaptive Biotechnologies' financial health and operational results, which can influence investor decisions.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of financial information and does not indicate any immediate or significant risks.
Key Players & Entities
- Adaptive Biotechnologies Corporation (company) — Registrant
- 0000950170-24-042291 (filing_id) — Accession Number
- April 2, 2024 (date) — Date of earliest event reported
- April 5, 2024 (date) — Filing Date
- 1165 Eastlake Avenue East Seattle, Washington 98109 (address) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on the Results of Operations and Financial Condition of Adaptive Biotechnologies Corporation.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported is April 2, 2024.
When was this 8-K form filed with the SEC?
This 8-K form was filed on April 5, 2024.
What is the company's principal executive office address?
The company's principal executive office is located at 1165 Eastlake Avenue East, Seattle, Washington 98109.
What is the Commission File Number for Adaptive Biotechnologies Corporation?
The Commission File Number for Adaptive Biotechnologies Corporation is 001-38957.
Filing Stats: 508 words · 2 min read · ~2 pages · Grade level 12.5 · Accepted 2024-04-05 16:30:14
Key Financial Figures
- $0.0001 — ch registered Common stock, par value $0.0001 per share ADPT The NASDAQ Stock Mar
Filing Documents
- adpt-20240402.htm (8-K) — 45KB
- adpt-ex99_1.htm (EX-99.1) — 18KB
- img119828894_0.jpg (GRAPHIC) — 8KB
- 0000950170-24-042291.txt ( ) — 194KB
- adpt-20240402.xsd (EX-101.SCH) — 29KB
- adpt-20240402_htm.xml (XML) — 4KB
02
Item 2.02 Results of Operations and Financial Condition. On April 2, 2024, Adaptive Biotechnologies Corporation (the " Company ") issued a press release that included, among other things, preliminary financial results for the quarter ended March 31, 2024. A copy of the press release is attached as Exhibit 99.1 and incorporated herein by reference. The information in this Item 2.02 and the press release attached as Exhibit 99.1 hereto shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release dated April 2, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Adaptive Biotechnologies Corporation Date: April 5, 2024 By: /s/ Chad Robins Chad Robins Chief Executive Officer